Browse by Series:

Bladder Cancer: Paradigm Changing Advances in Treatment

Evan Y. Yu, MD, Fred Hutchinson Cancer Research Center
Published: Friday, May 05, 2017



Transcript:

Evan Yu, MD:
The field of bladder cancer has changed dramatically since the approval of atezolizumab in this disease. Following the approval of atezolizumab, nivolumab has been FDA-approved as well. So, now we have both PD-L1 and PD-1 therapies available in this disease in the second-line setting and beyond. Recently, atezolizumab was also granted accelerated approval in the first-line setting for patients who have metastatic urothelial carcinoma and are cisplatin-ineligible because of significant renal dysfunction, neuropathy, hearing issues, or poor performance status.

This has changed everything dramatically. We now have more in our armamentarium to provide our patients, and we also really do have a survival benefit from the fact that pembrolizumab showed—in a randomized phase III trial in the second-line setting and beyond—that they were better than taxane chemotherapy in terms of overall survival. This has really changed a lot. Now our patients have more treatment options, can prolong their survival better, and the patients who do respond to this can get very durable responses with minimal toxicity. So, it’s a complete paradigm shift for the field, and we’re ecstatic to have this happen.

Transcript Edited for Clarity
SELECTED
LANGUAGE
Slider Left
Slider Right


Transcript:

Evan Yu, MD:
The field of bladder cancer has changed dramatically since the approval of atezolizumab in this disease. Following the approval of atezolizumab, nivolumab has been FDA-approved as well. So, now we have both PD-L1 and PD-1 therapies available in this disease in the second-line setting and beyond. Recently, atezolizumab was also granted accelerated approval in the first-line setting for patients who have metastatic urothelial carcinoma and are cisplatin-ineligible because of significant renal dysfunction, neuropathy, hearing issues, or poor performance status.

This has changed everything dramatically. We now have more in our armamentarium to provide our patients, and we also really do have a survival benefit from the fact that pembrolizumab showed—in a randomized phase III trial in the second-line setting and beyond—that they were better than taxane chemotherapy in terms of overall survival. This has really changed a lot. Now our patients have more treatment options, can prolong their survival better, and the patients who do respond to this can get very durable responses with minimal toxicity. So, it’s a complete paradigm shift for the field, and we’re ecstatic to have this happen.

Transcript Edited for Clarity
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x